Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
Cindy Strehl(Leibniz Association), Frank Buttgereit(German Rheumatism Research Centre), Maurizio Cutolo(Ospedale Policlinico San Martino), Simon Tarp(Frederiksberg Hospital), Annette de Thurah(Aarhus University Hospital), David Ray(Oxford Centre for Diabetes, Endocrinology and Metabolism), Joachim Listing(German Rheumatism Research Centre), N. Caeyers(National Patient Safety Foundation), Maarten Boers(Amsterdam University Medical Centers), Maarten de Wit(Cal Humanities), Xavier Mariette(Inserm), T. Huizinga(Leiden University Medical Center), Dieter Wiek(European League Against Rheumatism), Bhaskar Dasgupta(Anglia Ruskin University), J. W. J. Bijlsma(University Medical Center Utrecht), Raphaèle Séror(Inserm), Rinie Geenen(Utrecht University), William G Dixon(Manchester Academic Health Science Centre), Alison Kent(Salisbury NHS Foundation Trust), Kevin Winthrop(Oregon Health & Science University), Cornelia M Spies(Charité - Universitätsmedizin Berlin), Hans Ulrich Scherer(Leiden University)
Cited by 331
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k
Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products
|Journal of Biological Chemistry|2000|957